NeoImmuneTech (XKRX:950220) ROE % Adjusted to Book Value : -108.11% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NeoImmuneTech ROE % Adjusted to Book Value?

NeoImmuneTech's ROE % for the quarter that ended in Dec. 2023 was -57.30%. NeoImmuneTech's PB Ratio for the quarter that ended in Dec. 2023 was 0.53. NeoImmuneTech's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -108.11%.

NeoImmuneTech ROE % Adjusted to Book Value Historical Data

The historical data trend for NeoImmuneTech's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoImmuneTech ROE % Adjusted to Book Value Chart

NeoImmuneTech Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

-33.83

-64.97

-103.58

NeoImmuneTech Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial											-12.32	-71.12	-132.40	-151.38	-108.11

Competitive Comparison of NeoImmuneTech's ROE % Adjusted to Book Value

For the Biotechnology subindustry, NeoImmuneTech's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeoImmuneTech's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeoImmuneTech's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where NeoImmuneTech's ROE % Adjusted to Book Value falls into.

NeoImmuneTech ROE % Adjusted to Book Value Calculation

NeoImmuneTech's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-54.90%	/	0.53
	=	-103.58%

NeoImmuneTech's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-57.30%	/	0.53
	=	-108.11%

NeoImmuneTech ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of NeoImmuneTech's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

NeoImmuneTech (XKRX:950220) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeoImmuneTech Inc (XKRX:950220) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

2400 Research Boulevard, Suite 250, Rockville, MD, USA, 20850

Website

http://www.neoimmunetech.com

NeoImmuneTech Inc is a clinical-stage T cell-focused biotech company dedicated to the discovery and development of novel immuno-therapeutics. Its lead asset NT-I7 is the clinical stage IL-7, which enhances the body's immune function to address key resistance mechanisms in Immuno-Oncology and deadly infectious diseases.

NeoImmuneTech (XKRX:950220) Headlines

No Headlines